Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
Senseonics (NYSE American: SENS) reported preliminary unaudited Q3 2025 revenue of $8.1 million, a 91% increase versus Q3 2024, driven by ~160% new patient growth in the U.S. and record monthly new patient starts in September 2025. The company cited increased direct-to-consumer marketing and bringing sales and marketing in-house as drivers of momentum for its Eversense 365 CGM.
Senseonics also announced a 1-for-20 reverse stock split, reducing issued shares from ~816 million to ~41 million, expected effective at 5:00 p.m. ET on October 17, 2025, with post-split trading beginning October 20, 2025 under symbol SENS.
Senseonics (NYSE American: SENS) ha riportato ricavi preliminari non revisionati del Q3 2025 di 8,1 milioni di dollari, un aumento del 91% rispetto al Q3 2024, trainato da circa 160% di crescita di nuovi pazienti negli Stati Uniti e da avvii mensili record di nuovi pazienti nel settembre 2025. L'azienda ha citato un maggiore marketing diretto al consumatore e l'internalizzazione delle vendite e del marketing come motori della dinamica per il suo Eversense 365 CGM.
Senseonics ha inoltre annunciato una divisione azionaria rovesciata 1-for-20, che ridurrà le azioni emesse da circa 816 milioni a circa 41 milioni, prevista efficace alle 17:00 ET del 17 ottobre 2025, con il trading post-split a partire dal 20 ottobre 2025 sotto il simbolo SENS.
Senseonics (NYSE American: SENS) informó ingresos preliminares no auditados del tercer trimestre de 2025 de 8,1 millones de dólares, un incremento del 91% frente al 3T 2024, impulsado por un crecimiento de aprox. 160% de nuevos pacientes en EE. UU. y inicios mensuales récord de nuevos pacientes en septiembre de 2025. La empresa citó un aumento del marketing directo al consumidor y la internalización de ventas y marketing como impulsores de laMomentum para su Eversense 365 CGM.
Senseonics también anunció una división inversa de acciones 1-por-20, reduciendo las acciones emitidas de ~816 millones a ~41 millones, con efecto previsto a las 5:00 p.m. ET del 17 de octubre de 2025, con el inicio de operaciones post-split el 20 de octubre de 2025 bajo el símbolo SENS.
Senseonics(NYSE American: SENS)가 예비 미감사 Q3 2025 매출 $8.1백만, 전년동기 대비 91% 증가, 미국에서의 새로운 환자 성장 약 160% 및 2025년 9월에 기록된 월간 신규 환자 시작 건수로 견인되었습니다. 회사는 직접소비자 마케팅 확대와 영업 및 마케팅의 사내화가 Eversense 365 CGM의 모멘텀 원인이라고 밝혔습니다.
Senseonics는 또한 1:20의 역분할을 발표하여 발행주식을 약 8.16억주에서 약 4100만주로 축소하고, 2025년 10월 17일 오후 5시(Eastern Time)에 효력이 발생할 예정이며, 분할 후 거래는 2025년 10월 20일부터 SENS 기호로 시작됩니다.
Senseonics (NYSE American : SENS) a déclaré un chiffre d'affaires préliminaire non audité du T3 2025 de 8,1 millions de dollars, soit une hausse de 91% par rapport au T3 2024, tirée par une croissance d'environ 160% des nouveaux patients aux États-Unis et des démarrages mensuels record de nouveaux patients en septembre 2025. L'entreprise a cité une augmentation du marketing direct auprès des consommateurs et l'internalisation des ventes et du marketing comme moteurs de l'élan pour son Eversense 365 CGM.
Senseonics a également annoncé une opération de regroupement d'actions inversé de 1 pour 20, réduisant les actions émises d'environ 816 millions à environ 41 millions, prévue pour prendre effet à 17 h ET le 17 octobre 2025, avec une négociation après la scission à partir du 20 octobre 2025 sous le symbole SENS.
Senseonics (NYSE American: SENS) meldete vorläufige ungeprüfte Umsätze für das Q3 2025 in Höhe von 8,1 Mio. USD, ein Anstieg von 91% gegenüber Q3 2024, getrieben von ca. 160% neuem Patientenzuwachs in den USA und rekordhohen monatlichen Starts neuer Patienten im September 2025. Das Unternehmen führte vermehrtes Direct-to-Consumer-Marketing und die Inhouse-Vertrieb- und Marketing-Organisation als Treiber der Dynamik für seinen Eversense 365 CGM an.
Senseonics kündigte zudem eine 1-for-20-Splits an, wodurch die ausgegebenen Aktien von ca. 816 Millionen auf ca. 41 Millionen reduziert werden, voraussichtlich wirksam ab 17:00 Uhr ET am 17. Oktober 2025, mit Handelsaufnahme nach dem Split ab dem 20. Oktober 2025 unter dem Symbol SENS.
Senseonics (بورصة NYSE American: SENS) أبلغت عن إيرادات غير مدققة أولية للربع الثالث من 2025 تبلغ 8.1 مليون دولار، بزيادة 91% مقارنة بالربع الثالث من 2024، مدفوعة بنمو حوالي 160% في مرضى جدد في الولايات المتحدة وبدايات شهريّة قياسية لمرضى جدد في سبتمبر 2025. أشارت الشركة إلى زيادة التسويق المباشر للمستهلكين ودمج المبيعات والتسويق داخلياً كمحركات لزخم Eversense 365 CGM.
كما أعلنت Senseonics عن تقسيم عكسي للأسهم بنسبة 1 مقابل 20، مما سيخفض الأسهم المصدرة من نحو 816 مليوناً إلى نحو 41 مليوناً، ومن المتوقع أن يصبح ساري المفعول في الساعة 5:00 مساءً بتوقيت شرق الولايات المتحدة في 17 أكتوبر 2025، مع بدء التداول بعد التقسيم في 20 أكتوبر 2025 تحت الرمز SENS.
Senseonics (NYSE American: SENS) 报告称 2025 年第三季度初步未审计收入为 810 万美元，较 2024 年第三季度增长 91%，受美国新患者约 160% 的增长以及 2025 年 9 月新患者月度启动创纪录推动。公司表示，增加直接面向消费者的营销并将销售与市场营销内部化成为其 Eversense 365 CGM 动力的驱动因素。
Senseonics 还宣布实施 1 比 20 的反向股票分割，将发行在 external 的股数从约 8.16 亿股减少至约 4100 万股，预计在 2025 年 10 月 17 日美国东部时间下午 5:00 生效，分割后的交易将于 2025 年 10 月 20 日起以代码 SENS 开始交易。
- Revenue $8.1M in Q3 2025 (+91% YoY)
- U.S. new patient growth ~160% YoY
- Record monthly new patient starts in September 2025
- Reverse stock split 1-for-20 reducing issued shares from ~816M to 41M
- Outstanding equity awards and warrants will be reduced and exercise prices increased proportionally
Insights
Preliminary Q3 revenue rose to
Senseonics reported preliminary unaudited revenue of
Key dependencies and risks include sustaining DTC conversion efficiency and clinician adoption rates; revenue momentum depends on continued patient starts and retention. The reverse one‑for‑twenty stock split will reduce outstanding shares and adjust equity instruments effective at
Watch near‑term confirmation of final audited results and any updates to patient retention or unit economics within the next reporting cycle. Monitor the company communications around fractional share cash mechanics, the post‑split share count, and any reported changes in sales efficiency or clinician uptake over the following quarters.
Preliminary unaudited revenue of
Generated record quarterly new patient starts in Q3 2025
Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025
GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue for third quarter and provided a business update.
Senseonics generated preliminary unaudited revenue of approximately
Senseonics also today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-twenty (the “Reverse Stock Split”). The reverse stock split will reduce the number of shares of common stock issued from approximately 816 million shares to approximately 41 million shares, subject to adjustment due to payment of cash in lieu of fractional shares. The Company anticipates the Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 17, 2025 (the “Effective Time”). The Company's common stock will begin trading on a post-split basis at the market open on October 20, 2025. The Common Stock will continue trading on the NYSE American under the symbol “SENS,” with the new CUSIP number 81727U303.
Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics said, “I am excited by the team’s strong performance this quarter, which is a direct result of the increasing enthusiasm for Eversense 365, the world’s first and only year-long CGM. The ongoing investments we are making in our DTC marketing campaigns are accelerating awareness with patients and clinicians leading to the continued momentum behind Eversense. This is what encouraged us to bring the full sales and marketing organization in-house, giving us increased confidence in our ability to drive topline revenue and exceed patient expectations.”
The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on September 29, 2025 (the “Special Meeting”) to be effected at the Board's discretion within approved parameters. Following the Special Meeting, the final ratio was approved by the Company's Board on October 3, 2025.
As a result of the Reverse Stock Split, at the Effective Time, every twenty issued and outstanding shares of Common Stock will be converted into one share of Common Stock, with corresponding reductions in the Company’s (i) authorized shares of Common Stock, (ii) outstanding equity awards and warrants, and (iii) shares issuable under the Company's equity incentive plans and other existing agreements, with proportional increases in the exercise or conversion prices of outstanding options and warrants. The par value of each share of Common Stock will remain unchanged.
No fractional shares will be issued in connection with the Reverse Stock Split. Instead, each stockholder that otherwise would receive fractional shares will be entitled to receive, in lieu of such fractional shares, cash in an amount based on the closing price of the Common Stock on the NYSE American on the date of the Effective Time. The Reverse Stock Split will apply to all of the outstanding shares of Common Stock as of the Effective Time and therefore will not affect any stockholder’s ownership percentage of shares of Common Stock, except for de minimis changes resulting from the payment of cash in lieu of fractional shares. Stockholders of record will be receiving information from Computershare Trust Company, N.A., the Company’s transfer agent, regarding their stock ownership following the Reverse Stock Split and cash in lieu of fractional share payments, if applicable. Stockholders who hold their shares in brokerage accounts or in “street name” are not required to take any action in connection with the Reverse Stock Split.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.
Preliminary Unaudited Financial Results
This press release includes certain estimated preliminary financial results and other business metrics for the quarter ended September 30, 2025. These estimates are based on the information available to us at this time. Our actual results may vary from the estimated preliminary results presented here due to the completion of our financial closing procedures, final adjustments and other developments that may arise between now and the time the financial results for the quarter ended September 30, 2025 are finalized. The estimated preliminary financial results and other key business metrics have not been audited or reviewed by our independent registered public accounting firm. These estimates should not be viewed as a substitute for our full interim or annual financial statements. Accordingly, you should not place undue reliance on this preliminary data.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including the anticipated revenue results for the third quarter of 2025, and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to the previously announced decision to transition the commercialization of Eversense 365 from Ascensia to Senseonics, uncertainties inherent in the current reliance on the commercialization efforts and investment of Ascensia and its commercial initiatives, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties in the development of and competition in the overall CGM market, the risk that the share price resulting from a reverse stock split may not attract institutional or other investors, may not satisfy the investing guidelines of these investors, or otherwise may not result in increased investor interest in Senseonics’ stock or improved trading liquidity in the company’s stock, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors" and the Definitive Proxy Statement filed with the SEC on August 18, 2025 under the heading “Certain Risks and Potential Disadvantages Associated with a Reverse Stock Split.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
FAQ
What was Senseonics' reported preliminary revenue for Q3 2025 (SENS)?
How much did U.S. new patient starts grow for SENS in Q3 2025?
When is Senseonics' 1-for-20 reverse stock split for SENS effective?
How will the SENS reverse split change the share count?
Will SENS shareholders need to act for the reverse split?
What happens to SENS options and warrants after the reverse split?
